Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

Also called NCT02690974

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose supportive care
Phase
Phase 4
Enrolled
  • 302 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02690974
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02690974. Allocation not applicable; no masking; primary purpose supportive care. Start 2016-03-08 (actual); primary completion 2017-06-07 (actual). Results posted on 2019-06-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
Acronym
PARASAIL
Condition
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Intervention (Drug)
LCZ696 (sacubitril/valsartan)
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02690974
Content hash
61291947ec4c0670836ed6facdb82c45e0c60a155da426d4ebb3dda762888b3d